Human medicines European public assessment report (EPAR): Sprycel, dasatinib (anhydrous), Date of authorisation: 20/11/2006, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR): Sprycel, dasatinib (anhydrous), Date of authorisation: 20/11/2006, Revision: 48, Status: Authorised

Committee for Herbal Medicinal Products (HMPC): 6-8 July 2026, European Medicines Agency, Amsterdam, the Netherlands, from 6 July 2026 to 8 July 2026

Committee for Herbal Medicinal Products (HMPC): 6-8 July 2026, European Medicines Agency, Amsterdam, the Netherlands, from 6 July 2026 to 8 July 2026

Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of authorisation: 30/06/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of authorisation: 30/06/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Bysumlog, insulin lispro, Date of authorisation: 06/05/2026, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Bysumlog, insulin lispro, Date of authorisation: 06/05/2026, Revision: 2, Status: Authorised

Opinion on medicine for use outside EU: Ivermectin/Albendazole, ivermectin,albendazole, Parasitic Diseases,Helminthiasis,Hookworm Infections,Ascaridida Infections,Trichuriasis,Strongyloidiasis, 30/01/2025 Positive opinion

Opinion on medicine for use outside EU: Ivermectin/Albendazole, ivermectin,albendazole, Parasitic Diseases,Helminthiasis,Hookworm Infections,Ascaridida Infections,Trichuriasis,Strongyloidiasis, 30/01/2025 Positive opinion

Human medicines European public assessment report (EPAR): Riltrava Aerosphere, formoterol fumarate dihydrate,glycopyrronium,budesonide, Date of authorisation: 06/01/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Riltrava Aerosphere, formoterol fumarate dihydrate,glycopyrronium,budesonide, Date of authorisation: 06/01/2022, Revision: 7, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.